Torrent Pharmaceuticals Limited

Healthcare IN TORNTPHARM

4335.3999INR
-33.1001(0.76%)

Last update at 2026-06-04T09:48:00Z

Day Range

4328.104425.00

LowHigh

52 Week Range

2880.984104.80

LowHigh

Fundamentals

Previous Close 4368.50
Market Cap1362716.66M
Volume564972
P/E Ratio63.48
Dividend Yield-%
EBITDA39478.20M
Revenue TTM122480.90M
Revenue Per Share TTM361.87
Gross Profit TTM 92701.90M
Diluted EPS TTM63.43

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Income before tax	26728.10M	23521.10M	18470.00M	12259.10M	15262.60M
Minority interest	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Net income	19110.00M	16563.80M	12450.00M	7771.80M	12518.80M
Selling general administrative	7382.20M	7722.80M	6137.60M	5548.80M	5794.00M
Selling and marketing expenses	12606.70M	11296.80M	10269.90M	8849.10M	7426.30M
Gross profit	87401.90M	80416.30M	67290.00M	58813.30M	56509.30M
Reconciled depreciation	7950.00M	8080.00M	7070.00M	6620.00M	6580.00M
Ebit	29260.60M	25723.50M	21800.00M	19536.30M	18673.20M
Ebitda	36758.20M	33249.00M	28870.00M	26155.60M	25251.10M
Depreciation and amortization	7497.60M	7525.50M	7070.00M	6619.30M	6577.90M
Non operating income net other	-	-	-	-	-
Operating income	58883.50M	54979.90M	21400.20M	17693.40M	18227.70M
Other operating expenses	56277.40M	52298.50M	73290.00M	66494.60M	60578.60M
Interest expense	2520.00M	3535.60M	3330.00M	2529.30M	3561.60M
Tax provision	7620.00M	6960.00M	6020.00M	4490.00M	2740.00M
Interest income	2310.70M	114.80M	3330.00M	2550.00M	3580.00M
Net interest income	-2520.00000M	-3540.00000M	-3330.00000M	-2550.00000M	-3580.00000M
Extraordinary items	-	-	-	-	0.00000M
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	7615.60M	6957.30M	6020.00M	4487.30M	2743.80M
Total revenue	115160.90M	107278.40M	94640.00M	84188.00M	78862.30M
Total operating expenses	28518.40M	25436.40M	45940.00M	41119.90M	38225.60M
Cost of revenue	27759.00M	26862.10M	27350.00M	25374.70M	22353.00M
Total other income expense net	-32155.40000M	-31458.80000M	-2928.60000M	-5434.30000M	-2965.10000M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	19110.00M	16560.00M	12450.00M	7770.00M	12520.00M
Net income applicable to common shares	19112.50M	16563.80M	12450.00M	7771.80M	12518.80M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Total assets	149900.00M	150605.80M	150120.00M	130998.40M	140746.50M
Intangible assets	42630.00M	45828.20M	50890.00M	35460.60M	39840.30M
Earning assets	-	-	-	-	-
Other current assets	5240.00M	4841.10M	3030.00M	3120.00M	4510.00M
Total liab	73990.00M	82044.30M	88140.00M	71468.90M	82374.80M
Total stockholder equity	75910.00M	68561.50M	61980.00M	59529.50M	58371.70M
Deferred long term liab	-	-	-	-	-
Other current liab	10330.00M	8097.30M	1030.00M	990.00M	1280.00M
Common stock	1690.00M	1692.30M	1690.00M	846.20M	846.20M
Capital stock	1690.00M	1690.00M	1690.00M	846.20M	846.20M
Retained earnings	47465.50M	39424.00M	33031.90M	29166.80M	28064.70M
Other liab	-	-	-	5717.60M	3825.90M
Good will	3390.00M	3380.30M	3380.00M	2594.80M	3412.30M
Other assets	6217.30M	5821.70M	5436.70M	6848.00M	5293.00M
Cash	5790.00M	8351.40M	5080.00M	3984.00M	5725.60M
Cash and equivalents	2315.20M	3992.90M	379.80M	228.10M	149.30M
Total current liabilities	47170.00M	54252.50M	54470.00M	44150.90M	48916.20M
Current deferred revenue	-	45.00M	8460.00M	7320.40M	7859.50M
Net debt	26230.00M	31868.00M	48600.00M	36712.50M	43015.70M
Short term debt	18640.00M	23537.00M	28190.00M	19096.10M	19108.60M
Short long term debt	18340.00M	23340.00M	28010.00M	18950.00M	7040.00M
Short long term debt total	32020.00M	40219.40M	53680.00M	40696.50M	48741.30M
Other stockholder equity	-2504.90000M	714.30M	27258.10M	29516.50M	29460.80M
Property plant equipment	38229.10M	35777.70M	34598.40M	32469.30M	36287.50M
Total current assets	56230.00M	56114.80M	53140.00M	51649.90M	55215.00M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	21474.10M	15119.10M
Short term investments	1144.90M	1410.00M	3270.00M	1845.50M	1654.50M
Net receivables	18670.00M	18443.00M	19460.00M	18077.20M	16512.90M
Long term debt	11920.00M	16040.00M	24960.00M	21230.00M	29410.00M
Inventory	25410.00M	22790.70M	22300.00M	24623.20M	26812.00M
Accounts payable	18200.00M	20893.20M	16790.00M	16744.40M	20668.10M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	26749.10M	27445.20M	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	8859.40M	3233.50M	1958.90M	3208.10M	1093.60M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	93670.00M	94491.00M	96980.00M	79348.50M	85531.50M
Capital lease obligations	1760.00M	840.00M	710.00M	520.00M	486.70M
Long term debt total	13376.10M	16682.40M	25491.50M	21600.00M	29632.70M

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Investments	-5400.00000M	-1680.00000M	-24150.00000M	-80.90000M	-1206.50000M
Change to liabilities	-	-	-	-4576.70000M	1295.20M
Total cashflows from investing activities	-5400.00000M	-1679.00000M	-24150.00000M	-1966.30000M	-4494.20000M
Net borrowings	-9255.00000M	-13694.40000M	-	-8464.40000M	-9562.90000M
Total cash from financing activities	-22980.00000M	-27796.40000M	770.00M	-17810.50000M	-16561.30000M
Change to operating activities	-	-	-	-	-
Net income	19110.00M	16563.80M	18470.00M	12259.10M	15262.60M
Change in cash	-2621.40000M	3266.10M	1100.00M	-1741.60000M	-892.60000M
Begin period cash flow	8351.40M	5085.30M	3980.00M	5725.60M	6618.20M
End period cash flow	5730.00M	8351.40M	5080.00M	3984.00M	5725.60M
Total cash from operating activities	25850.00M	32660.80M	23680.00M	18029.90M	20106.90M
Issuance of capital stock	-	-	-	-	-
Depreciation	7950.00M	7953.00M	7070.00M	6619.30M	6577.90M
Other cashflows from investing activities	74.60M	1467.80M	-18410.00000M	72.40M	52.50M
Dividends paid	10830.00M	10153.40M	-8630.00000M	-6768.90000M	-3384.50000M
Change to inventory	-2620.00000M	-490.00000M	2560.00M	2188.80M	-5329.80000M
Change to account receivables	171.70M	780.00M	-2897.20000M	-1091.10000M	652.10M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-2895.00000M	-3948.60000M	19120.00M	-711.80000M	1202.20M
Change to netincome	-	-	-	7157.30M	4397.50M
Capital expenditures	6110.00M	4327.80M	5740.00M	2025.70M	3351.50M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-4809.30000M	45.30M	-180.00000M	-3518.50000M	-3382.50000M
Stock based compensation	-	-	-	-	-
Other non cash items	3599.30M	8098.70M	-1680.00000M	2670.00M	1648.90M
Free cash flow	19740.00M	28333.00M	17940.00M	16004.20M	16755.40M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (INR)	Price (INR)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
TORNTPHARM Torrent Pharmaceuticals Limited	-33.1001 0.76%	4335.40	63.48	56.50	11.13	16.39	11.65	35.91
SUNPHARMA Sun Pharmaceutical Industries Limited	-7.0 0.39%	1781.50	40.32	26.95	7.69	5.50	7.41	23.64
DIVISLAB Divi's Laboratories Limited	21.00 0.32%	6597.50	70.47	-	17.47	11.44	17.33	47.08
CIPLA Cipla Limited	24.70 1.80%	1399.90	21.74	19.01	4.23	3.76	4.08	14.00
DRREDDY Dr. Reddy's Laboratories Limited	4.90 0.39%	1268.20	17.16	21.93	2.94	2.89	2.99	10.39

Reports Covered

View All

Profile

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.

Torrent Pharmaceuticals Limited

Torrent House, Ahmedabad, India, 380009

91 79 2659 9000
https://www.torrentpharma.com
Employees : 17059

Key Executives

Name	Title	Year Born
Mr. Samir Uttamlal Mehta	Exec. Chairman & MD	1964
Mr. Jinesh Shah B.Sc., MBA	Exec. Director of Operations & Whole Time Director	1977
Mr. Sudhir Menon CA, CWA	Exec. Director of Fin. & CFO	1972
Mr. Chintan Trivedi	Company Sec. & Compliance Officer	NA
Mr. Abdullah Salam Said Al Abri	Chief Customer Service Officer	NA
Mr. R. Chandrashekhar Inter CA	VP of Procurement	1969
Jaydip Bhatt	VP of Human Resource	1953
H. L. Guttikar B.E., MMS	VP of Projects	1963
Ashish Hajarnish M.Pharm	VP of Works	1968
Hasmukh Patel B.Pharm, M.Pharm.	VP of Works	1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.